JP2004075689A5 - - Google Patents

Download PDF

Info

Publication number
JP2004075689A5
JP2004075689A5 JP2003311358A JP2003311358A JP2004075689A5 JP 2004075689 A5 JP2004075689 A5 JP 2004075689A5 JP 2003311358 A JP2003311358 A JP 2003311358A JP 2003311358 A JP2003311358 A JP 2003311358A JP 2004075689 A5 JP2004075689 A5 JP 2004075689A5
Authority
JP
Japan
Prior art keywords
methylerythromycin
powder
ray diffraction
solvate
substantially free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003311358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004075689A (ja
Filing date
Publication date
Priority claimed from US08/785,623 external-priority patent/US5945405A/en
Application filed filed Critical
Publication of JP2004075689A publication Critical patent/JP2004075689A/ja
Publication of JP2004075689A5 publication Critical patent/JP2004075689A5/ja
Withdrawn legal-status Critical Current

Links

JP2003311358A 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態0 Withdrawn JP2004075689A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP53437298A Division JP4058114B2 (ja) 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態0

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008327022A Division JP5190350B2 (ja) 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態0

Publications (2)

Publication Number Publication Date
JP2004075689A JP2004075689A (ja) 2004-03-11
JP2004075689A5 true JP2004075689A5 (cg-RX-API-DMAC7.html) 2005-10-27

Family

ID=25136084

Family Applications (3)

Application Number Title Priority Date Filing Date
JP53437298A Expired - Lifetime JP4058114B2 (ja) 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態0
JP2003311358A Withdrawn JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態0
JP2008327022A Expired - Lifetime JP5190350B2 (ja) 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態0

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP53437298A Expired - Lifetime JP4058114B2 (ja) 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態0

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008327022A Expired - Lifetime JP5190350B2 (ja) 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態0

Country Status (18)

Country Link
US (1) US5945405A (cg-RX-API-DMAC7.html)
EP (1) EP1077988A1 (cg-RX-API-DMAC7.html)
JP (3) JP4058114B2 (cg-RX-API-DMAC7.html)
KR (1) KR100567149B1 (cg-RX-API-DMAC7.html)
CN (1) CN1174991C (cg-RX-API-DMAC7.html)
AR (3) AR011077A1 (cg-RX-API-DMAC7.html)
AU (1) AU735598B2 (cg-RX-API-DMAC7.html)
BR (1) BR9714287A (cg-RX-API-DMAC7.html)
CA (4) CA2387361C (cg-RX-API-DMAC7.html)
CZ (1) CZ297433B6 (cg-RX-API-DMAC7.html)
DE (1) DE97951771T1 (cg-RX-API-DMAC7.html)
ES (1) ES2173058T1 (cg-RX-API-DMAC7.html)
IL (1) IL130255A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ336073A (cg-RX-API-DMAC7.html)
TR (1) TR199901578T2 (cg-RX-API-DMAC7.html)
TW (1) TW574224B (cg-RX-API-DMAC7.html)
WO (1) WO1998031699A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA98116B (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
CZ20021999A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
CA2397092A1 (en) 2000-01-11 2001-07-19 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
DE60122791T2 (de) * 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
ATE432691T1 (de) * 2000-03-28 2009-06-15 Sandoz Ag Geschmackmaskierte granulierte teilchen
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
CA2418135C (en) * 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
AU2002327418A1 (en) * 2001-08-01 2003-02-17 Bristol-Myers Squibb Company Taste masking composition
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (en) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
CA2538856C (en) * 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシンa誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンa誘導体の製造方法
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンa誘導体およびその製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンaオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
PT915899E (pt) * 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Similar Documents

Publication Publication Date Title
JP2009137975A5 (cg-RX-API-DMAC7.html)
CN100413879C (zh) 4″-取代-9-脱氧-9a-氮杂-9a-高红霉素A衍生物的制备方法
JP5190350B2 (ja) クラリスロマイシンの結晶形態0
CN1216892C (zh) 甲红霉素的晶形i
Bright et al. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides
TW472060B (en) 4""-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
JP3262806B2 (ja) C−4”置換マクロライド誘導体
JP4589110B2 (ja) 抗炎症性活性を有するマクロライド化合物
JP4102440B2 (ja) 新規なエリスロマイシン誘導体、それらの調製方法及びそれらの医薬品としての使用
HUP0204091A2 (hu) Eljárások a clarithromycin polimorf módosulatainak előállítására és az új polimorf IV módosulat, és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AU710532B2 (en) 3-descladinose-2,3-anhydroerythromycin derivatives
WO2007010555A2 (en) Novel crystalline forms of moxifloxacin hydrochloride and process for preparation thereof
JP2004528336A (ja) アジスロマイシン水和物の1,2−プロピレングリコール包接化合物、その製造方法およびそれを含む医薬組成物
KR20060015750A (ko) 지프라시돈 HCl의 다형 형태 및 그 제조 방법
CN1351607A (zh) 大环内酯抗生素的新晶形
CN1238364C (zh) 红霉素衍生物,其制备方法及其作为药物的用途
JP2003501439A5 (cg-RX-API-DMAC7.html)
ES2254389T3 (es) Agentes anti-infecciosos utiles contra cepas bacterianas resistntes a multiples farmacos.
JP2007527434A (ja) 非晶質タクロリマス及びその調製
CN1798755A (zh) O-烷基大环内酯和氮杂内酯衍生物和制备这些化合物的区域选择性方法
KR100467707B1 (ko) 클래리트로마이신의 제 2결정형의 제조 방법
US6667338B2 (en) 9-amino erythromycin derivatives with antibacterial activity
WO2005061524A2 (en) Process for the preparation of form ii clarithromycin
TW200946109A (en) Anti-bacterial activity of 9-hydroxy derivatives 6, 11-bicyclolides
JP2008544970A (ja) 抗炎症活性を有するマクロライド化合物の結晶体